A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment
This study is testing a new medication called zanidatamab mixed with chemotherapy to see if it works better than standard treatment. It is designed specifically for people whose HER2-positive breast cancer has spread and has not responded well to previous treatments.
You might be able to join if you are an adult with metastatic HER2-positive breast cancer that has continued to grow after previous treatment with trastuzumab deruxtecan. Your overall health and medical history will also be checked by the study team to make sure it is safe for you.
Participants will be randomly placed into one of two groups to receive either the new zanidatamab combination or the standard treatment combination. You will have regular check-ups with the medical team to monitor your health and see how your body responds to the treatment.
This study is currently recruiting participants at medical centers in locations such as Phoenix and Tucson, Arizona. More locations may be available, so the study team can help you find the most convenient spot.
- 1Testing a new targeted cancer drug called zanidatamab with chemotherapy
- 2Comparing the new treatment against a standard medication option
- 3Currently recruiting participants at multiple locations in Arizona
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.